文献速递冠心病肺血管病与心包/心肌炎

利伐沙班联合阿司匹林在血管疾病合并肾功能不全患者中的应用:COMPASS试验

Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial.
PubMed 文献 · J Am Coll Cardiol · 2019-01-01

COMPASS试验的二次分析纳入27,395例慢性冠心病或外周动脉疾病患者,其中21,111例基线估算肾小球滤过率(GFR)≥60 ml/min,6,276例GFR<60 ml/min。在肾功能不全患者中,主要疗效终点(心血管死亡、心肌梗死或卒中)和大出血均更常见,且事件频率与GFR呈负相关。但无论GFR分层如何,利伐沙班2.5 mg每日两次联合阿司匹林均一致降低主要终点,且未发现出血风险额外增加。

要点

  • 在GFR≥60 ml/min患者中,利伐沙班联合阿司匹林较单用阿司匹林降低主要终点(HR 0.76,95%CI 0.64-0.90)。
  • 在GFR<60 ml/min患者中,联合治疗同样降低主要终点(HR 0.75,95%CI 0.60-0.94)。
  • 联合治疗增加大出血风险,但肾功能不全患者未见出血风险额外增加。

核心结论

  • 在合并中度肾功能不全的血管疾病患者中,利伐沙班2.5 mg每日两次联合阿司匹林较单用阿司匹林的心血管获益得以保持,且未发现出血风险额外增加。

研究设计与样本

  • COMPASS试验的二次分析,纳入27,395例慢性冠心病或外周动脉疾病患者,其中21,111例基线GFR≥60 ml/min,6,276例GFR<60 ml/min。

主要发现

  • 肾功能不全患者中主要疗效终点和大出血均更常见,且事件频率与GFR呈负相关。
  • GFR≥60 ml/min患者中,联合治疗组主要终点发生率3.5%,单用阿司匹林组4.5%(HR 0.76,95%CI 0.64-0.90)。
  • GFR<60 ml/min患者中,联合治疗组主要终点发生率6.4%,单用阿司匹林组8.4%(HR 0.75,95%CI 0.60-0.94)。
  • GFR≥60 ml/min患者中,联合治疗组大出血发生率2.9%,单用阿司匹林组1.6%(HR 1.81,95%CI 1.44-2.28)。
  • GFR<60 ml/min患者中,联合治疗组大出血发生率3.9%,单用阿司匹林组2.7%(HR 1.47,95%CI 1.05-2.07)。

临床怎么用

  • 对于合并中度肾功能不全的慢性冠心病或外周动脉疾病患者,可考虑使用利伐沙班2.5 mg每日两次联合阿司匹林以降低缺血事件风险,同时警惕大出血风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic kidney disease is associated with an increased risk of both bleeding and ischemic cardiovascular events. OBJECTIVE: The purpose of this study was to determine the balance of risks and benefits from the dual pathway antithrombotic regimen (rivaroxaban 2.5 mg twice daily [bd] plus aspirin, compared with aspirin) in vascular patients with or without moderate renal dysfunction. METHODS: This was a secondary analysis of the COMPASS (Cardiovascular OutcoMes for People using Anticoagulation StrategieS) trial involving 27,395 patients with chronic coronary or peripheral artery disease. RESULTS: In COMPASS, 21,111 patients had an estimated glomerular filtration rate (GFR) at baseline of ≥60 ml/min, 6,276 had a GRF of <60 ml/min. Both the primary efficacy outcome (cardiovascular death, myocardial infarction, or stroke) and major bleeding were more frequent in those with renal dysfunction, and the frequency of these outcome events was inversely related to GFR. However, the primary outcome was consistently reduced with rivaroxaban 2.5 mg bd plus aspirin, irrespective of GFR category (GFR ≥60 ml/min, 3.5% rivaroxaban plus aspirin, 4.5% aspirin alone, hazard ratio [HR]: 0.76, 95% confidence interval [CI]: 0.64 to 0.90; GFR <60 ml/min, 6.4% rivaroxaban plus aspirin, 8.4% aspirin alone, HR: 0.75; 95% CI: 0.60 to 0.94). Major bleeding was more frequent with rivaroxaban 2.5 mg plus aspirin versus aspirin alone in those with GFR ≥60 ml/min (2.9% rivaroxaban plus aspirin, 1.6% aspirin alone, HR: 1.81; 95% CI: 1.44 to 2.28) and similarly in those with GFR <60 ml/min (3.9% rivaroxaban plus aspirin, 2.7% aspirin alone, HR: 1.47, 95% CI: 1.05 to 2.07). CONCLUSIONS: The benefits of the dual pathway COMPASS regimen (rivaroxaban 2.5 mg bd plus aspirin), versus aspirin alone, are preserved in patients with moderate renal dysfunction without evidence of an excess hazard of bleeding.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Fox KAA, Eikelboom JW, Shestakovska O, et al. Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial. J Am Coll Cardiol. 2019. PMID: 31072566. doi:10.1016/j.jacc.2019.02.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。